Trifluiridine/tipiracil

3
ESMO-MCBS v1.1
Scorecard version: 1

Indication details

Tumour Type
Gastrointestinal
Tumour Sub-type
Gastric and gastro-oesophageal junction cancers
Control Arm
Placebo
Treatment Setting
Patients who have been treated with two prior lines of chemotherapy 
Trial Name
TAGS

Primary Outcome(s)

Primary Outcome(s)
OS
Form(s)
Form 2a

Outcome Data

OS Control
3.6 months
OS Gain
2.1 months
OS HR
0.69 (0.56-0.85)

Final Score (after adjustments)

Preliminary non-curative score
3
Final non-curative Score
3
Issue date
06.11.2019

DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; HR, hazard ratio; iDFS, invasive disease-free survival; ITT, intention to treat; mDoR, median duration of response; mPFS, median progression-free survival; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings